Search
Sotrovimab
go.drugbank.com/drugs/DB16355ApprovedInvestigational[L34425, L34430, L34440] However, in April 2022, the FDA removed the EUA for sotrovimab due to the rising COVID-19 cases caused by the Omicron BA.2 sub-variant, where the drug is ineffective. … found to reduce the risk of death or hospitalization in high-risk adults with COVID-19 in the outpatient setting.
Cilgavimab
go.drugbank.com/drugs/DB16393ApprovedInvestigationalCilgavimab, in combination with [tixagevimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for … [L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022.
Tixagevimab
go.drugbank.com/drugs/DB16394ApprovedInvestigationalTixagevimab, in combination with [cilgavimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for … [L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022.
Isatuximab
go.drugbank.com/drugs/DB14811ApprovedInvestigationalIsatuximab (formerly SAR650984) is a humanized, IgG1-derived monoclonal antibody (mAb) produced from a Chinese hamster ovary (CHO) cell line. … [L12099] It is a cytolytic antibody targeted against CD38, a glycoprotein found on the surface of some immune cells that is highly expressed by malignant plasma cells in multiple myeloma.
Vestronidase alfa
go.drugbank.com/drugs/DB12366ApprovedInvestigationalVestronidase alfa, or vestronidase alfa-vjbk, is a recombinant human lysosomal beta glucuronidase that is a purified enzyme produced by recombinant DNA technology in a Chinese hamster ovary cell line. … MPS VII is a progressive condition that affects most tissues and organs due to the lack of a lysosomal enzyme called beta-glucuronidase, leading to buildup of toxic metabolites.
Canagliflozin
go.drugbank.com/drugs/DB08907ApprovedInvestigationalIt was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type … Cardiovascular disease is the most common cause of death in these patients [A177083].
Mixtures: INVOKANA DUOCategories: Drugs Used in DiabetesMoxifloxacin
go.drugbank.com/drugs/DB00218ApprovedInvestigationalBayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
Mixtures: TQ OFTAMOX D UD®, TQ OFTAMOX® D UDProducts: MOXIFLOXACINA DOUBLE-E PHARMA, TQ OFTAMOX® UDNiclosamide
go.drugbank.com/drugs/DB06803ApprovedInvestigationalVet approvedThey are an even greater problem in domestic animals. Niclosamide, once marketed in the US under the brand name Niclocide, was voluntarily withdrawn from market by Bayer in 1996.[L11860] … Niclosamide is an antihelminthic used for the treatment of tapeworm infections.
Categories: Compounds used in a research, industrial, or household settingGlycyrrhizic acid
go.drugbank.com/drugs/DB13751ApprovedInvestigational[T204] Glycyrrhizic acid has been developed in Japan and China as a hepatoprotective drug in cases of chronic hepatitis. … [F80] It was approved by Health Canada to be used in over-the-counter products but all the products are currently on the status canceled post marketed.[L1113]
Pimozide
go.drugbank.com/drugs/DB01100ApprovedA diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome.
Categories: Dopamine D2 Receptor Antagonists